Physician profile
Mohammad Akmal
NPI 1356378087
$804.08
in general payments reported to CMS, 2019-2025
12 companies · $226 in 2025
The $226 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2021: $11.10 · 2022: $55.68 · 2023: $93.47 · 2024: $213 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $215.38 | 2019-2025 | Vafseo, Auryxia |
| Glaxosmithkline, LLC. | $139.30 | 2023-2024 | Benlysta |
| Smith+Nephew, INC. | $114.22 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $107.26 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $57.76 | 2023-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $55.51 | 2024-2025 | Lupkynis |
| Travere Therapeutics, INC. | $34.74 | 2023 | |
| Ardelyx, INC. | $26.22 | 2024 | Ibsrela |
| Opko Pharmaceuticals, LLC | $16.03 | 2022 | |
| Pfizer INC. | $13.42 | 2019 | |
| Mallinckrodt Hospital Products INC. | $13.14 | 2023 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Akmal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.